Summary
Signal counts
Assets tracked: 1
Watchlist assets: 1
Registry stop assets: 1
Sponsor overview
VelosBio ., a subsidiary of Merck & Co., . (Rahway, New Jersey USA)
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT04504916 | https://clinicaltrials.gov/study/NCT06395103
Assets
Linked programs
- Zilovertamab vedotin: Registry Stop Signal (4/5)